18 and older, any sex, with Gout or Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3Primary· Phase III of the study (weeks 49-72 of study duration)
Participants were defined as flaring in Phase 3 if they:
-1) met 3 of 4 following participant-reported criteria:
* a) warm joint(s)
* b) swollen joint(s)
* c) pain (\>3) at rest on a scale of 0-10 (10 being the worst pain)
* d) self-identified gout flare
OR
-2) reported use of medications to treat flare
Group
Value
95% CI
Allopurinol / Sham Comparator (Febuxostat)
135
Febuxostat / Sham Comparator (Allopurinol)
165
Adverse events — posted to ClinicalTrials.gov
Time frame: Beginning at informed consent and continuing until the end of participation in the study at 72 weeks, plus 30 days of observation..
Reporting threshold: 1%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attacks. These therapies have never been compared at appropriate doses. Further, they will be studied in patients with kidney disease for the first time.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07414394 — Tigulixostat (IBI128) vs Febuxostat in Gout
· Phase 3
· recruiting
NCT07367971 — Drug-Drug Interaction Study of ABP-671 in Gout Patients
· Phase 1
· recruiting
NCT07346079 — Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
· Phase 4
· recruiting
NCT07089875 — A Study of Dotinurad Versus Allopurinol in Participants With Gout
· Phase 3
· recruiting
NCT05507723 — Tight Control of Gouty Arthritis Compared to Usual Care
· NA
· recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care
· Phase 1
· not yet recruiting
NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran
· NA
· not yet recruiting
NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness
· NA
· not yet recruiting
NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
· NA
· not yet recruiting
NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
Last refreshed: 29 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02579096.